Who are Rebif® new formulation (RNF)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Peginterferon alfa-2b Injection, Pegyinterferon-alfa-2a, Peg-IFN + WB RBV for 24 weeks, Placebo and peginterferon, INF1.0 + IBU, Pegylated IFN- alpha 2b.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rebif-new-formulation-rnf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Rebif® new formulation (RNF) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rebif® new formulation (RNF) (Rebif® new formulation (RNF)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Immunology.

phase 3 Interferon IFNAR Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Rebif® new formulation (RNF) (Rebif® new formulation (RNF)) — EMD Serono Research & Development Institute, Inc.. Rebif new formulation (RNF) is an interferon beta-1a used to treat multiple sclerosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rebif® new formulation (RNF) TARGET	Rebif® new formulation (RNF)	EMD Serono Research & Development Institute, Inc.	phase 3	Interferon	IFNAR
Peginterferon alfa-2b Injection	Peginterferon alfa-2b Injection	Nanfang Hospital, Southern Medical University	marketed	Interferon alfa	Interferon-alpha receptor (IFNAR)
Pegyinterferon-alfa-2a	Pegyinterferon-alfa-2a	Chinese University of Hong Kong	marketed	Pegylated interferon	Interferon-alfa receptor (IFNAR)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Placebo and peginterferon	Placebo and peginterferon	National Taiwan University Hospital	marketed	Interferon alpha (pegylated)	Interferon-alpha receptor (IFNAR)
INF1.0 + IBU	INF1.0 + IBU	St. Justine's Hospital	marketed	Interferon alfa + NSAID combination	Interferon alfa receptor (IFNAR); COX-1 and COX-2
Pegylated IFN- alpha 2b	Pegylated IFN- alpha 2b	Ain Shams University	marketed	Interferon-alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rebif® new formulation (RNF) — Competitive Intelligence Brief. https://druglandscape.com/ci/rebif-new-formulation-rnf. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing